With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.33821-94-2,2-(3-Bromopropoxy)tetrahydro-2H-pyran,as a common compound, the synthetic route is as follows.
To a mixture of 4-iodo-lH-pyrazole (2.0 g, 10.3 mmol) and Cs2CO3 (5.04 g, 15.5 mmol) in MeCN (28 mL) was added 2-(3- bromopropoxy)tetrahydro-2H-pyran (1.84 mL, 10.8 mmol) and the mixture stirred at T overnight. The crude reaction mixture was poured into water and extracted with EtOAc (x 3). The combined organic layers were washed with brine, dried (MgSO4) and concentrated in vacuo. The resulting residue was purified by FCC, using a gradient of 0-80% EtOAc in cyclohexane, to give the title compound (2.95 g, 81%). NMR (300 MHz, CDC13): 150- 1.58 (4H, m), 1.65-1.90 (2H, m), 2.12 (2H, qn, J = 6.4 Hz), 3.35 (1H, dt, J = 10.2, 5.9 Hz), 3.46-3.54 (1H, m), 3.73 (1H, dt, J = 10.2, 5.9 Hz), 3.80-3.88 (1H, m), 4.26 (2H, td, J = 6.9, 1.5 Hz), 4.54 (1H, dd, J = 4.5, 3.1 Hz), 7.46 (1H, s), 7.50 (1H, s)., 33821-94-2
As the paragraph descriping shows that 33821-94-2 is playing an increasingly important role.
Reference£º
Patent; CHIESI FARMACEUTICI S.P.A.; ALCARAZ, Lilian; PANCHAL, Terry Aaron; JENNINGS, Andrew Stephen Robert; CRIDLAND, Andrew Peter; HURLEY, Christopher; WO2014/194956; (2014); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics